Marijuana Watch: Aurora Marijuana makes its long-awaited push into the U.S. with Reliva CBD acquisition

Marijuana Watch.

Aurora shares rise almost 30%in the extended session.


Cannabidiol, or CBD, is a non-intoxicating aspect of the cannabis plant.

Ethan Miller/Getty Images.

Over a year after Aurora Marijuana Inc. executives started openly talking about making a push into the U.S. market, the company has made its move: the $40 million all-stock purchase of a cannabidiol maker called Reliva.

Though Aurora.


will issue roughly 2 million shares to make the purchase, shares rose nearly 30%in the prolonged session Wednesday.

The carefully held Reliva LLC makes products that consist of cannabidiol, or CBD, which is a non-intoxicating aspect of the cannabis plant.

Don’t miss: ‘ CBD has the possible to damage you,’ FDA warns consumers

In the statement, Aurora stated that Reliva’s management team will continue to run the U.S. company, with its president taking the title of president, U.S.

Reliva’s site sells a range of CBD products including beverage mix, gummies, lip balm, family pet inctures and skin cream.

See likewise: Cronos paid $300 million for a little CBD business, and CEO’s private-equity company stands to gather $120 countless it

The U.S. just recently legislated hemp, but left controling CBD to the Fda, which has taken a decidedly careful approach At the moment, business are not permitted to include CBD to food, drinks or cosmetic items, and the FDA has actually been punishing companies that do so.

The FDA’s stance has actually shown tough for a few of Aurora’s rivals. Cronos Group Inc.

said in a current teleconference that it had pulled strategies to release a CBD brand name in the U.S., and mentioned regulatory unpredictability, among other things.

Aurora’s stock has actually been on a roller-coaster ride in the past year, falling to the point of being threatened with delisting before executing a reverse stock split and seeing the freshly bundled shares spike— to two times the marketplace value of rival OrganiGram Holdings Inc.’s.

— after a revenues report that revealed much better pot sales than expected.

Cannabis Watch: See all of MarketWatch’s cannabis protection here

Discover more